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Abstract
Introduction—The significance of pancreas divisum (PD) as a risk factor for pancreatitis is 
controversial. We analyzed the characteristics of children with PD associated with acute recurrent 
(ARP) or chronic pancreatitis (CP) to better understand its impact.
Patients and methods—We compared children with or without PD in the well-phenotyped 
INSPPIRE (INternational Study group of Pediatric Pancreatitis: In search for a cuRE) cohort. 
Differences were analyzed using two-sample t-test or Wilcoxon rank sum test for continuous 
variables, Pearson Chi-square or Fisher's exact test for categorical variables.
Results—PD was found in 52 of 359 (14.5%) subjects, a higher prevalence than the general 
population (~ 7%). Females more commonly had PD (71% vs 55%; p=0.02). Children with PD 
did not have a higher incidence of mutations in SPINK1, CFTR, CTRC compared to children with 
no PD. Children with PD were less likely to have PRSS1 mutations (10% vs 34%; p<0.01) or a 
family history of pancreatitis (p<0.05), and more likely to have hypertriglyceridemia (11% vs 3%; 
p=0.03). Children with PD underwent significantly more endoscopic procedures and pancreatic 
sphincterotomy. Patients with PD had fewer attacks of acute pancreatitis (p=0.03) and were less 
likely to develop exocrine pancreatic insufficiency (p=0.01). Therapeutic ERCP was considered 
most helpful if pancreatic duct was impacted with stones (83% helpful).
Conclusions—PD is likely a risk factor for ARP and CP in children that appears to act 
independently of genetic risk factors. Patients with PD and stones obstructing the pancreatic duct 
benefit most from therapeutic ERCP.
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INTRODUCTION
Pancreas divisum (PD), caused by the failure of ventral and dorsal pancreatic buds to fuse, is 
a common congenital anomaly of the pancreas [1, 2]. Pooled analysis of 23 autopsy studies 
demonstrates a PD incidence of 7.8% (95% CI 6.8–8.8)[3]. Studies showing a higher 
frequency of PD in adult patients with idiopathic pancreatitis [4] suggest that PD is a risk 
factor for pancreatitis. The postulated pathogenesis for pancreatitis in patients with PD is 
functional obstruction at the minor papilla that prevents effective drainage of the dorsal 
pancreatic duct, thereby increasing intraductal pressure. This theory is supported by studies 
describing a clinical benefit from therapeutic drainage interventions.[5–7]
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In contrast, some studies have questioned the role of PD in the development of pancreatitis 
and its contribution to the pathogenesis of pancreatitis as controversial. The majority of 
individuals with PD (>95%) are asymptomatic, with PD detected during autopsy or by 
imaging done for reasons other than pancreatic disease. [1–3] Other studies did not find an 
increased frequency of PD in patients with idiopathic pancreatitis [8] or a change in the 
natural history of alcoholic chronic pancreatitis (CP) if PD was present.[9, 10] In addition, 
not all studies show a benefit from therapeutic interventions. Thus, it is not clear whether 
there is a causal relationship between PD and risk for acute recurrent pancreatitis (ARP) and 
CP and whether endoscopic or surgical interventions benefit patients with PD, or if a subset 
of patients may benefit from endoscopic therapy. Most studies are retrospective or small case 
series without proper controls.[6, 7, 11, 12] Finally, several studies have reported an 
association of PD with genetic variants that in themselves increase risk for pancreatitis (i.e. 
cystic fibrosis transmembrane conductance regulator (CFTR), serine protease inhibitor 
Kazal-type 1 (SPINK1)).[8, 13, 14] These authors proposed that PD alone does not cause 
pancreatitis, but may be a co-factor or “the second hit” that contributes to the development 
of pancreatitis.
The literature on PD has primarily focused on adults. It is not known whether PD alone or in 
combination with genetic or other risk factors leads to the development of ARP and CP in 
childhood. Because the majority of children with ARP or CP have genetic risk factors [15, 
16] whereas most adult disease is associated with alcohol, tobacco and gallstones [17], we 
hypothesized that PD is an additional risk factor for childhood ARP and CP, likely in 
combination with the presence of genetic variants.
To address our hypothesis, we took advantage of the well-characterized INternational Study 
Group of Pediatric Pancreatitis: In search for a cuRE (INSPPIRE) cohort of children with 
ARP or CP. [18, 19] Herein, we compare children in our database with and without PD to 
determine if PD is more common than expected in the general population and whether PD 
associates with genetic risk factors or other clinical characteristics of children with ARP or 
CP. Our objective is to improve our limited understanding of this anatomical anomaly.
MATERIALS AND METHODS
Demographic and clinical information of children with ARP or CP ≤19 years of age at the 
time of enrollment were entered into the Research Electronic Data Capture (REDCap™, 
Vanderbilt University, Nashville, TN)™ at nineteen INSPPIRE centers. The complete data 
entered to the database between September 2012 and August 2017 were included and 
represented baseline information of the INSPPIRE cohort. The INSPPIRE database 
structure, patient inclusion and exclusion criteria and the specific information collected from 
the physician-completed questionnaires have been previously described.[19] All subjects 
met the criteria for ARP or CP as previously defined by INSPPIRE.[18] Diagnosis of PD 
was made by magnetic retrograde cholangiopancreatography (MRCP), endoscopic 
retrograde cholangiopancreatography (ERCP) or both performed at each participating center. 
Information related to all other radiological studies including computerized tomography 
(CT), and endoscopic ultrasound (EUS) was collected from the physician questionnaires. All 
sites obtained Institutional Review Board approval or the equivalent for their country for this 
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study. Written consent was obtained from the parent or guardian and assent was obtained 
from children 11 years or older.
Data presented from some of the patients in this study were published in references 15 and 
16.
Statistical Analysis
Summary statistics used were mean with standard deviation (SD) or median with 
interquartile range (IQR) according to the normality of distribution. Differences between 
children with or without PD were analyzed using two-sample t-test or Wilcoxon-rank sum 




Among 359 children with ARP or CP, a total of 52 (14.5%) were identified as having PD. 
This prevalence is higher than the reported prevalence for the general population (~7%) [3]. 
Females were more likely to have PD than were males (PD-71% vs no PD-55%, p=0.02) 
(Table 1). Otherwise, patients with PD did not differ in race, ethnicity, age at first diagnosis 
of acute pancreatitis (AP), CP or time interval from AP to CP. Patients with PD did not have 
an increased frequency of CP (54% vs 53%, p=0.92). The majority of children with or 
without PD were white (>80%).
Associated Risk Factors
Children with PD were significantly less likely to have a family history of AP (PD-16% vs 
no PD-31%, p=0.04) or CP (PD-9% vs no PD-25%, p=0.02) when compared with subjects 
without PD (Table 2).
Genetic testing for at least one mutation was performed in 303 subjects (PD: 43/52, no PD: 
260/307). Among the evaluated pancreatitis-associated mutations, the protease serine 1 
(PRSS1) gene mutation was tested most frequently (n=277), followed by CFTR (n=264), 
SPINK1 (n=257) and trypsinogen-degrading enzyme chymotrypsin C (CTRC; n=175). 
CFTR (15/41, 37%) and SPINK1 (12/40, 30%) were the most common mutations identified 
in the PD subjects; PRSS1 was the most common mutation identified in the subjects without 
PD (79/235, 34%). The prevalence of CFTR, SPINK1 or CTRC mutations did not differ 
between subjects with or without PD (CFTR p=0.28, SPINK1 p=0.17, CTRC p=0.40). 
PRSS1 mutations were found at a lower frequency in subjects with PD (PD-10% vs no 
PD-34%, p<0.01) (Table 2).
PD was found less commonly in children with PRSS1 mutations (4/83, 5%) than in children 
with CFTR (15/81, 19%), SPINK1 (12/56, 21%) or CTRC mutations (3/12, 25%). If PD was 
present along with at least one genetic mutation, the likelihood of CP was high (PD with any 
mutation 17/22 CP (77%) vs PD with no mutation 7/21 CP (33%), p<0.01). This finding 
seemed to be independent of PD as patients with genetic mutations who did not have PD 
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also had a high chance of having CP (no PD with any mutation 110/161 CP (68%) vs no PD 
with no mutation 36/99 CP (36%), p<0.001).
Other obstructive factors were uncommon in both groups, with 5 in PD group and 43 
subjects without PD having at least one obstructive factor (Table 2). At least one toxic-
metabolic risk factor was identified in 11 subjects with PD, and in 74 subjects without PD. 
Interestingly, hypertriglyceridemia was more common in subjects with PD (11% vs 3%, 
p=0.03).
Imaging Studies
All of the patients in this study had an MRCP (174 patients) or ERCP (46 patients) or both 
(139 patients). Patients with CP were more likely to have both MRCP and ERCP compared 
to patients with ARP (CP-52% vs ARP-23%, p=0.001) whereas patients with ARP were 
more likely to have had only an MRCP (CP-29% vs ARP-71%, p=0.001). When both tests 
were done, PD was found more frequently with ERCP than with MRCP although the 
difference was not significant (ERCP-90% vs MRCP-68%, p=0.06). Patients with PD were 
more likely to have an ERCP than patients without PD (PD-71% vs no PD-51%, p<0.01) 
(Table 3). The other imaging methods were performed at similar rates for those with and 
without PD including MRI (PD-67% vs no PD-74%, p=0.34), CT (PD-52% vs no PD-49%, 
p=0.68) and EUS (PD-17% vs no PD-13%, p=0.36). It was not known whether secretin was 
used with MRCP in 66 of the total 313 subjects who had MRCP only or MRCP and ERCP; 
it was utilized in a subset of subjects in both groups (PD: 10/52, 19%; no PD: 45/307, 15%). 
The frequency of abnormal imaging findings was similar between subjects with and no PD 
although a non-significant trend was present for a greater frequency of main pancreatic duct 
irregularities in PD (PD-56% vs. no PD-40%, p=0.07) and pancreatic duct dilatation 
(PD-58% vs. no PD-41%, p=051).
Treatments
We tracked treatment options including medical (analgesics, anti-oxidants and pancreatic 
enzyme replacement therapy), endoscopic and surgical therapies in children with ARP or 
CP. We found no difference in utilization of medical or surgical therapies between the 
groups (Table 4).
Pancreatic sphincterotomy was performed more frequently in patients with PD (54% vs 
28%, p<0.001); biliary sphincterotomy was more common in non-PD group (4% vs 22%, 
p<0.01) (Table 4). Twenty children had minor papillotomy only; two major papilla 
sphincterotomy (minor papillotomy was unsuccessful in 1) and four a combination of major 
and minor papilla sphincterotomy. Of 27 children who underwent minor papillotomy for PD, 
pancreatic duct dilatation (dorsal, ventral or both) was found in 17 (63%), 9 had no 
dilatation, unknown in 1. In patients with PD, pancreatic sphincterotomy or minor 
papillotomy was found most helpful by the treating physician if done for pancreatic ductal 
stones (5/6 patients or 83%). Therapeutic ERCP in patients with PD was less helpful for 
abdominal pain (11/20 patients or 55%), acute recurrent pancreatitis (9/24 patients or 38%) 
and overall for at least one reason (13 of 27 patients or 48%). In patients without PD, 
pancreatic sphincterotomy was also most helpful if done for pancreatic ductal stone (24 of 
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39 patients or 62%). Patients with abdominal pain (19 of 58 patients or 33%), ARP (17/69 
patients or 10%) and overall for at least one reason (37 of 81 patients or 46%) had poorer 
responses to treatment.
Disease Burden
Children with PD had fewer attacks of pancreatitis per year (p=0.02) (Table 5). Compared to 
children without PD, children with PD were less likely to develop exocrine pancreatic 
insufficiency in the time-frame of the study (9% vs 25%, p=0.01). No significant differences 
were found in the frequency or nature of pancreatitis-related pain, emergency room visits or 
number of hospitalizations between the groups. The frequency of diabetes was no different 
between the groups (8% vs 7%, p=0.76).
DISCUSSION
We previously reported that genetic and obstructive lesions are the primary risk factors for 
ARP and CP in children.[16] In this study, we focused on the role of PD as an obstructive 
risk factor for pediatric ARP and CP. PD was found in 14.6% of children with ARP or CP, 
which is significantly greater than the incidence reported in the general population [3]. Fogel 
et al. reviewed the literature for reports of the PD prevalence determined by autopsy, ERCP 
or MRCP in the general population [3]. The prevalence of PD was 7.8% by autopsy, 3.5% 
by ERCP, and 7.1% by MRCP. The PD prevalence in children was significantly higher than 
the reported PD prevalence by autopsy studies (226 PD in 2895 subjects or 7.8%, 
p=<0.001), by ERCP (1413 PD in 39,632 subjects or 3.5%, p=<0.001) and by MRCP (188 
PD in 2231 subjects, 8.4%, p=<0.001) [3]. A recent MRCP study of healthy individuals 
found a prevalence of 9.6% [20]. Of course, we have compared the PD prevalence in 
children to studies of adults and there is a possibility of technical bias for ERCP and MRCP 
because of the smaller size of many pediatric patients. Even so, the technical bias associated 
with smaller spatial resolution and difficulty in accessing and injecting the dorsal pancreatic 
duct would underestimate the prevalence of PD in children. Thus, our findings support the 
conclusion that PD is a risk factor for ARP and CP in children.
Interestingly, we found the majority of children with PD to be female (72%) whereas 
children without PD were equally distributed in gender. Lucidi et al observed a similar trend 
in their ARP pediatric cohort where 60% of subjects with structural abnormalities including 
PD were noted to be female.[21] Despite this intriguing observation, the clinical relevance of 
female sex and how it may influence susceptibility to pancreatitis or interact with PD to 
increase risk remains unclear.
The association between PD and pancreatitis-related genetic mutations has been reported in 
adult patients with idiopathic pancreatitis.[8, 22, 23] In all cases, PD was reported as a “co-
factor” or as participating in a “two-hit” phenomenon to increase the susceptibility to 
pancreatitis. A potential association between PD and CFTR mutations has received the 
greater attention.[8, 22, 23] Bertin et al found the frequency of PD to be no different in 
patients with idiopathic pancreatitis (5%) and controls (7%), yet, the combined presence of 
CFTR and PD was significantly higher (47%) suggesting perhaps they interact as cofactors 
in the development of pancreatitis. We did not find an increased incidence of genetic 
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mutations in patients with PD. We have to note that only 84% of our cohort underwent at 
least one gene testing for known pancreatitis-associated mutations (PRSS1, SPINK1, CFTR, 
CTRC) and many did not have all 4 genes tested. Thus, we cannot reliably conclude that PD 
interacted with genetic risk factors to cause CP in our cohort.
When comparing subjects with and without PD, we identified significantly lower number of 
children with PD as having a family history of pancreatitis and the PRSS1 genetic variant. 
Given the autosomal dominant mode of inheritance for PRSS1 with a disease penetrance of 
>80% [24, 25], it may not be surprising that non-PD group has a more frequent family 
history of AP and CP. In addition, only 5% of children with PRSS1 mutations had PD, much 
lower than the remainder of the cohort. The negative association of PD with PRSS1 
mutations in this study is most curious. In a pediatric ARP and CP cohort from Korea, 4 of 6 
children had SPINK1 or PRSS1 mutations and children with PD plus a mutation were more 
likely to have CP [26]. We have found a high likelihood of CP in children with PD and 
genetic mutations, but this seemed to be driven by genetic variants, not PD. The negative 
association of PRSS1 mutations with PD needs further investigation.
The only toxic or metabolic risk factors we observed to have an increased association with 
PD in our patients was hypertriglyceridemia. To our knowledge, an association between PD 
and hypertriglyceridemia has not been previously reported. Hypertriglyceridemia is a well-
known risk for AP in children and adults.[27, 28] In a recent review of adults with 
hypertriglyceridemia and pancreatitis, a large number had ARP and a smaller subset had CP 
suggesting elevated triglycerides may be a risk factor for ARP and CP.[29] Most patients 
with hypertriglyceridemia had other risk factors such as obesity, poorly controlled diabetes 
mellitus, use of medications associated with AP, heavy alcohol consumption or smoking. 
The authors did not report the incidence of PD in the population. The explanation for why 
we found an association between PD and hypertriglyceridemia and not with other risk 
factors is not clear.
We did not observe a higher disease burden (increased pain, ER visits, hospitalizations, 
medical or surgical therapies) in children with PD, compared with children without PD. 
Children with PD underwent significantly more ERCPs and pancreatic sphincterotomies 
(specifically minor papillotomy) and were less likely to have acute attacks and exocrine 
pancreatic insufficiency (EPI) compared with the non-PD group over the study period. 
Biliary sphincterotomy was performed only in 3 children with PD for unclear reasons. It has 
to be noted that the data were obtained from the treating physician in the form of a 
questionnaire. To adequately interpret the utility of endoscopic procedures in PD, future 
studies require adequate power, detailed histories and endoscopic findings, type of 
endoscopic intervention performed (e.g. papillotomy +/− stent placement, stone extraction, 
stricture dilation), in addition to short- and long-term outcomes.
Despite defining the PD diagnosis based on standard criteria (radiographic imaging or direct 
ductal opacification during ERCP), it is possible that PD diagnosis was under-reported due 
to diagnostic limitations of MRCP and ERCP including the omission of secretin in some 
cases which has been shown to increase the MRCP sensitivity and specificity for the 
detection of PD.[30] Due to the variable MRCP imaging protocols at each INSPPIRE site, 
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secretin-MRCP was not standardized in all cases and its usage was left to the discretion and 
routine practice of the participating institution. In the future, secretin-MRCP should be 
considered for the diagnosis of pancreatic ductal disease or anomalies.
Although ERCP is the gold standard for PD confirmation, our physician-completed 
questionnaires did not collect information on ERCP success rates of obtaining an adequate 
or complete pancreatogram via the major and minor papilla, therefore it is possible true PD 
failed to be appropriately diagnosed in some cases. However, the pervasiveness of this 
potential limitation is unlikely given that an active effort would be made by the therapeutic 
endoscopist to prove or disprove the presence of abnormal or atypical pancreatic ductal 
anatomy at the time of ERCP.
EUS is an alternative method for diagnosing PD.[31, 32] The INSPPIRE physician-
completed questionnaire for EUS findings was designed to mainly collect information 
related to findings that would be supportive of CP and the development of complications 
including pancreatic cysts. Therefore, EUS data cannot be used for the diagnosis of PD in 
this study.
The prevalence of PD in the INSPPIRE cohort of children with ARP or CP is greater than 
the prevalence reported in the healthy adult population. The prevalence of PD was 
significantly lower in patients with PRSS1 mutations. The prevalence of CFTR, SPINK1, 
CTRC did not differ statistically with the presence or absence of PD. Still, more than half of 
patients with PD tested for genetic risk variants carried at least one genetic risk variant. The 
presence of PD should not preclude genetic testing for other genetic risk factors in children. 
Patients with PD and ductal obstruction benefit most from therapeutic ERCP. Additional 
research is needed to better define the role of PD in the onset and progression of pediatric 
pancreatitis and the role of interventional ERCP in therapy.
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Table 1






Sex (Female) 37 (71%) 168 (55%) 0.02
(n=51) (n=281)
Ethnicity (Hispanic) 11 (22%) 74 (26%) 0.47
Race (n=45) (n=263)
  White 37 (82%) 221 (84%) 0.95
  African American 2 (4%) 8 (3%)
  Asian 2 (4%) 15 (6%)
  Multi-racial 3 (7%) 14 (5%)
  Other 1 (2%) 5 (2%)
Age at first diagnosis of AP (n=47) (n=289)
  Mean±SD 8.7±4.3 8.7±4.7 0.91
  Range 2.2–18.2 0.4–18.4
With CP 28 (54%) 163 (53%) 0.92
Age at diagnosis of CP (n=22) (n=150)
  Mean±SD 10.1±3.8 10.2±4.3 0.96
  Range 3.4–17.4 1.5–18.0
Time from AP to CP, years (n=47) (n=293)
  Median (25th–75th percentile) 3.1 (1.4–7.6) 2.9 (0.6–7.7) 0.57
PD, pancreas divisum; AP, acute pancreatitis; CP, chronic pancreatitis; SD: Standard deviation
Significant p values are highlighted
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  Acute pancreatitis 7/43 (16%) 79/252 (31%) 0.04
  Chronic pancreatitis 4/43 (9%) 64/257 (25%) 0.02
Genetic Risk Factors:
  PRSS1 4/42 (10%) 79/235 (34%) <0.01
  SPINK1 12/40 (30%) 44/217 (20%) 0.17
  CFTR 15/41 (37%) 66/223 (28%) 0.28
  CTRC 3/27 (11%) 9/148 (6%) 0.40
Obstructive factors
  Sphincter of Oddi disorders 2/50 (4%) 8/295 (3%) 0.64
  Gallstones 1 (2%) 14/299 (5%) 0.70
  Pancreatic duct mal-union 1/51 (2%) 13/299 (4%) 0.70
  Post-traumatic pancreatic stricture 0/50 (0%) 2/301 (1%) 1.0
  Preampullary duodenal diverticulum 0/51 (0%) 1/301 (0.3%) 1.0
  Duct obstruction 1 (2%) 8/301 (3%) 1.0
  Annular pancreas 0 (0%) 3/301 (1%) 1.0
  Biliary cyst 0 (0%) 8/302 (3%) 0.61
Toxic/Metabolic
  Alcoholic 0 (0%) 4/306 (1%) 1.0
  Active/Passive smoking exposure 3/49 (6%) 23/296 (8%) 1.0
  Hypertriglyceridemia 5/44 (11%) 9/266 (3%) 0.03
  Medications 1/45 (2%) 27/282 (10%) 0.14
  Autoimmune pancreatitis 0/43 (0%) 8/246 (3%) 0.61
  Other autoimmune diseases 4/50 (8%) 21/294 (7%) 0.77
  Crohn’s disease 0/49 (0%) 1/291 (0.3%) 1.0
  Ulcerative colitis 1/50 (2%) 2/291 (1%) 0.38
  Intedeterminate colitis 0/49 (0%) 2/291 (1%) 1.0
  Azathioprine or 6-MP treatment 0/50 (0%) 3/292 (1%) 1.0
ARP: Acute Recurrent Pancreatitis; CP: Chronic Pancreatitis; PD, pancreas divisum; PRSS1, protease serine 1; SPINK1, serine protease inhibitor 
Kazal-type 1; CFTR, cystic fibrosis transmembrane conductance regulator; CTRC, trypsinogen-degrading enzyme chymotrypsin C; 6-MP, 6-
mercaptopurine
Significant p values are highlighted
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   ERCP 37 (71%) 158 (51%) <0.01
     Number ERCP (range) (1–12) (1–9)
  1 21 88
  2 7 36
  3 5 14
   ≥4 4 20
   CT scan 27 (52%) 150 (49%) 0.68
   MRI 35 (67%) 226 (74%) 0.34
   EUS 9 (17%) 39 (13%) 0.36
Findings (any imaging)
  Focal Acute Pancreatitis 5/36 (14%) 33/240 (14%) 1.0
  Inflammatory changes 14/36 (39%) 84/242 (35%) 0.62
  Enlarged Pancreas 7/36 (19%) 55/242 (23%) 0.65
  Cysts/Pseudocysts 10/52 (19%) 49/307 (16%) 0.55
  Peripancreatic inflammation/fat stranding 16/39 (41%) 82/246 (33%) 0.34
  Gallstones/Sludge 3/36 (8%) 16/241 (7%) 0.72
  Pancreatic Atrophy 11/37 (30%) 70/245 (29%) 0.88
  PD stricture 15/49 (31%) 70/295 (24%) 0.30
  PD irregularities 20/36 (56%) 97/245 (40%) 0.07
  PD dilatation 21/36 (58%) 101/246 (41%) 0.05
  Calcifications 4/37 (11%) 24/243 (10%) 0.77
  CBD stricture 2/51 (4%) 18/305 (6%) 0.75
  CBD dilatation 8/52(15%) 58/306 (19%) 0.53
  CBD stones 1/52 (2%) 25/307 (8%) 0.14
  Intraheptic biliary dilatation 4/36 (11%) 27/245 (11%) 1.0
  Abnormal Side Branches 18/50 (36%) 80/296 (27%) 0.19
  Changes suggestive of cirrhosis and/or portal hypertension 2/36 (6%) 13/241 (5%) 1.0
  Main Pancreatic Duct - Abnormal 33/52 (63%) 160/303 (53%) 0.15
  Intraductal filling defects of calculi 9/52 (17%) 57/300 (19%) 0.77
ARP: Acute Recurrent Pancreatitis; CP: Chronic Pancreatitis; PD, pancreas divisum; ERCP, endoscopic retrograde cholangiopancreatography; CT, 
computed tomography; MRI, magnetic resonance imaging; EUS, endoscopic ultrasound; CBD, common bile duct
Significant p values are highlighted
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  Pain medications 20/49 (41%) 121/274 (44%) 0.66
  Pancreatic enzymes 20/50 (40%) 105/273 (38%) 0.83
  Vitamins/antioxidants 17/50 (34%) 118/276 (43%) 0.24
  Steroids 0/50 (0%) 8/276 (3%) 0.61
  Diabetic medications 3/50 (6%) 22/277 (8%) 0.77
Endoscopic Therapies
  Any ERCP 31/50 (62%) 152/305 (50%) 0.11
  Biliary sphincterotomy 2/49 (4%) 66/299 (22%) <0.01
  Pancreatic sphincterotomy 27/50 (54%) 83/298 (28%) <0.001
  Pancreatic duct stent placement 17/50 (34%) 80/301 (27%) 0.27
  Biliary stent placement 1/50 (2%) 17/301 (6%) 0.48
  Pancreatic duct stone removal 6/50 (12%) 47/300 (16%) 0.50
Surgical Therapies
  Any Pertinent Surgeries 12 (23%) 81/305 (27%) 0.59
  Cholecystectomy 4 (8%) 41/304 (13%) 0.24
  Celiac nerve block 1 (2%) 5/304 (2%) 1.0
  Cyst/pseudo-cyst operation 1 (2%) 13/304 (4%) 0.70
  Lateral pancreaticojejonstomy 2 (4%) 14/304 (4%) 1.0
  Partial pancreatectomy 0 (0%) 2/304 (1%) 1.0
  TPIAT 5 (10%) 34/304 (11%) 1.0
ARP: Acute Recurrent Pancreatitis; CP: Chronic Pancreatitis; PD, pancreas divisum; PERT, pancreatic enzyme replacement therapy; ERCP, 
endoscopic retrograde cholangiopancreatography; TPIAT, total pancreatectomy with islet auto-transplantation
Significant p values are highlighted
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Pattern of abdominal pain (n=49) (n=276)
- no abdominal pain 4 (8%) 35 (13%) 0.65
- usually pain free; episodes of mild-moderate pain 9 (18%) 40 (14%)
- constant mild-moderate pain 2 (4%) 15 (5%)
- usually pain free; episodes of severe pain 16 (33%) 93 (34%)
- constant mild-moderate pain+ episodes of severe pain 15 (31%) 76 (28%)
- constant severe pain 3 (6%) 17 (6%)
Constant Pain score (n=45) (n=261)
   Median (IQR) 0 (0–17) 0 (0–0) 0.21
   Range 0–92 0–100
   With any level of constant pain 16 (36%) 62 (24%)
Episodic Pain score (n=40) (n=254)
   Median (IQR) 66.5 (33–79.5) 60 (9–84) 0.98
   Range 0–100 0–100
   With any level of episodic pain 34 (85%) 195 (77%)
Number of ER visits – lifelong (average/yr) (n=36) (n=206)
   Median (IQR) 1.7 (1.0–3.7) 1.6 (0.5–2.9) 0.40
   Range 0–25 0–18
Number of ER visits – past year (n=45) (n=261)
   Median (IQR) 2 (1–3) 2 (0–3) 0.20
   Range 0–12 0–30
Number of hospitalizations – lifelong (average/yr) (n=41) (n=205)
   Median (IQR) 1.6 (1.0–3.6) 1.5 (0.5–2.8) 0.29
   Range 0–25 0–18
Number of hospitalizations – past year (n=45) (n=263)
   Median (IQR) 2 (1–3) 1 (0–3) 0.38
   Range 0–13 0–23
Days missed school past month (n=38) (n=221)
   Median (IQR) 3 (0–10) 1 (0–6) 0.11
   Range 0–30 0–180
Abdominal pain related to pancreatitis 36/48 (75%) 247/299 (83%) 0.20
Exocrine insufficiency 4/45 (9%) 70/277 (25%) 0.01
Endocrine insufficiency 4/50 (8%) 21/297 (7%) 0.76





















Number of acute pancreatitis attacks per year (n=37) (n=225)
   Median (IQR) 1.4 (0.6–2.0) 1.8 (0.9–3.4) 0.02
   Range 0–25 0–66
ARP: Acute Recurrent Pancreatitis; CP: Chronic Pancreatitis; ER: Emergency Room; IQR: interquartile range
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